Final answer:
Selegiline is the specific inhibitor of monoamine oxidase type B among the options given, and it is primarily used in the treatment of Parkinson's disease.
Step-by-step explanation:
Selegiline, a medication employed primarily in Parkinson's disease treatment, acts as a selective inhibitor of monoamine oxidase B (MAO-B) at recommended doses. MAO-B is an enzyme responsible for breaking down neurotransmitters in the brain. Selegiline's selectivity for MAO-B implies a preference for inhibiting the specific isoform associated with Parkinson's pathology, leading to increased levels of neurotransmitters like dopamine. In contrast, other options like Moclobemide, Phenelzine, Tranylcypromine, and Befloxatone either exhibit less selectivity in inhibiting monoamine oxidase or are not as specific to the MAO-B isoform. Selegiline's targeted action enhances its therapeutic efficacy while minimizing the risk of side effects associated with non-selective MAO inhibition, making it a valuable and specific tool in managing Parkinson's disease and related neurological conditions.